Ceralasertib together with Imfinzi (durvalumab) didn't meet the first endpoint of general survival (OS) within the section 3 LATIFY trial versus standard-of-care docetaxel in...
Remedy with Trodelvy (sacituzumab govitecan-hziy) elicited fewer uncomfortable side effects that led to dose discount or stopping therapy altogether in contrast with...
The 2025 American Society of Hematology Annual Assembly in December in Orlando, Florida was crammed with momentum, discovery and significant conversations, and...
